|
Name |
(1S,5S,6S)-5-hydroxy-4-methoxy-6-methyl-7-oxabicyclo[4.1.0]hept-3-en-2-one
|
| Molecular Formula | C8H10O4 | |
| IUPAC Name* |
(1S,5S,6S)-5-hydroxy-4-methoxy-6-methyl-7-oxabicyclo[4.1.0]hept-3-en-2-one
|
|
| SMILES |
C[C@]12[C@H](C(=CC(=O)[C@H]1O2)OC)O
|
|
| InChI |
InChI=1S/C8H10O4/c1-8-6(10)5(11-2)3-4(9)7(8)12-8/h3,6-7,10H,1-2H3/t6-,7+,8-/m0/s1
|
|
| InChIKey |
AIVUQNKTJDAYQX-RNJXMRFFSA-N
|
|
| Synonyms |
(4s,5s,6s)-5,6-epoxy-4-hydroxy-3-methoxy-5-methyl-cyclohex-2-en-1-one; (1S,5S,6S)-5-hydroxy-4-methoxy-6-methyl-7-oxabicyclo[4.1.0]hept-3-en-2-one; (4S,5S,6S)-4-Hydroxy-3-methoxy-5-methyl-5,6- epoxycyclohex-2-en-1-one; (1beta)-4-Methoxy-5alpha-hydroxy-6beta-methyl-7-oxabicyclo[4.1.0]hepta-3-ene-2-one; 7-Oxabicyclo[4.1.0]hept-3-en-2-one, 5-hydroxy-4-methoxy-6-methyl-, (1S,5S,6S)-
|
|
| CAS | NA | |
| PubChem CID | 5275343 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 170.16 | ALogp: | -0.9 |
| HBD: | 1 | HBA: | 4 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 59.1 | Aromatic Rings: | 2 |
| Heavy Atoms: | 12 | QED Weighted: | 0.565 |
| Caco-2 Permeability: | -4.556 | MDCK Permeability: | 0.00001930 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.006 |
| Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.005 |
| 30% Bioavailability (F30%): | 0.01 |
| Blood-Brain-Barrier Penetration (BBB): | 0.858 | Plasma Protein Binding (PPB): | 27.50% |
| Volume Distribution (VD): | 1.112 | Fu: | 80.38% |
| CYP1A2-inhibitor: | 0.012 | CYP1A2-substrate: | 0.886 |
| CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.859 |
| CYP2C9-inhibitor: | 0.005 | CYP2C9-substrate: | 0.078 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.303 |
| CYP3A4-inhibitor: | 0.007 | CYP3A4-substrate: | 0.413 |
| Clearance (CL): | 8.745 | Half-life (T1/2): | 0.915 |
| hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.112 |
| Drug-inuced Liver Injury (DILI): | 0.834 | AMES Toxicity: | 0.506 |
| Rat Oral Acute Toxicity: | 0.818 | Maximum Recommended Daily Dose: | 0.031 |
| Skin Sensitization: | 0.252 | Carcinogencity: | 0.727 |
| Eye Corrosion: | 0.948 | Eye Irritation: | 0.877 |
| Respiratory Toxicity: | 0.058 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005472 | ![]() |
1.000 | D03SKD | ![]() |
0.198 | ||
| ENC005579 | ![]() |
0.465 | D0U4VT | ![]() |
0.188 | ||
| ENC004165 | ![]() |
0.426 | D0X5KF | ![]() |
0.188 | ||
| ENC004166 | ![]() |
0.426 | D06XMU | ![]() |
0.182 | ||
| ENC004965 | ![]() |
0.413 | D0R9VR | ![]() |
0.179 | ||
| ENC004966 | ![]() |
0.413 | D09JBP | ![]() |
0.176 | ||
| ENC004964 | ![]() |
0.354 | D0L1WV | ![]() |
0.174 | ||
| ENC004168 | ![]() |
0.347 | D0K7LU | ![]() |
0.174 | ||
| ENC004167 | ![]() |
0.347 | D03DIG | ![]() |
0.173 | ||
| ENC003147 | ![]() |
0.346 | D0T6RC | ![]() |
0.173 | ||